Exact Sciences again expects to beat Street estimates

Colorectal cancer diagnostics company Exact Sciences Corp. (NASDAQ:EXAS) released preliminary 4Q17 and full-year revenues that exceed analysts' expectations. The company

Read the full 200 word article

User Sign In